Supreme Court upholds mail access to abortion pill mifepristone for now

The Supreme Court has decided to maintain mail access to the abortion pill mifepristone, temporarily setting aside a lower court’s order that restricted its distribution through telehealth and mail. This decision ensures that patients across the U.S. can continue to access mifepristone while a legal challenge from Louisiana against the FDA’s relaxed policy is ongoing. Conservative Justices Samuel Alito and Clarence Thomas dissented. The case arose after a federal appellate court reinstated a rule requiring in-person dispensing of the drug, which two pharmaceutical companies argued caused confusion. Louisiana officials wanted to keep the stricter rule, claiming it allowed out-of-state providers to bypass the state’s abortion ban. The FDA did not take a position on the matter. The Supreme Court’s intervention follows the overturning of Roe v. Wade, which led to increased restrictions on abortion in many states. Mifepristone, used with misoprostol, is a key component in medication abortions, which accounted for 65% of all clinician-provided abortions in 2023. QUESTION: How might the Supreme Court’s decision to maintain mail access to mifepristone impact the future of abortion rights and access in the United States?